Pfizer, Starboard
Pfizer appointed a former chief executive officer at Vanguard, the drug giant's biggest investor, to its board on Tuesday as ...
As a long-term holding, Pfizer should benefit from demographic trends driving increased healthcare spending globally. The ...
Barely three years since its coronavirus vaccine helped stem the pandemic, Pfizer’s stock has lost 50 percent of its value ...
Guggenheim has earned $172 million from advising Pfizer on nearly $400 billion in acquisitions since 2011. Pfizer’s stock ...
Pfizer taps Triana to discover molecular glues for cancer and beyond in deal potentially worth $1.5B
Big Pharma is sticking to the recent molecular glue investment trend, with Pfizer now the latest major drugmaker to get in on ...
The activist investment firm Starboard Value has launched a proxy fight again Pfizer, questioning the company’s management ...
Now, despite playing no formal role in the battle between Pfizer and Starboard, Guggenheim has found itself in the crossfire of one of the messiest activist campaigns in recent Wall Street memory.
The new drug would allow patients to produce the needed clotting protein for an extended period, reducing the need for ...
Former Pfizer CEO Ian Read and ex-CFO Frank D'Amelio said they will not be involved with activist investor Starboard Value, ...
Pfizer will apply Triana Biomedicines’ target-first and proximity-first discovery platform to discover molecular glue degraders for unspecified “multiple” targets in oncology and several other ...
Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback